Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses

Vaccine

Volumn 29, Issue 34, 2011, Pages 5645-5651

  Yin, Ying ^a   Li, Hao ^a   Wu, Shipo ^a   Dong, Dayong ^a   Zhang, Jun ^a   Fu, Ling ^a   Xu, Junjie ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

ESAT 6; Hepatitis B virus core particle; Immune carrier; Mycobacterium tuberculosis; Vaccine

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; HEPATITIS B CORE ANTIGEN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTRON MICROSCOPY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; TH1 CELL; VIRUS LIKE AGENT;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SYNTHETIC;

EID: 79960554606     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.012     Document Type: Article

References (42)

1. Gupta U.D., Katoch V.M., McMurray D.N. Current status of TB vaccines. Vaccine 2007, 25(19):3742-3751.
2. WHO Global tuberculosis control-surveillance, planning, financing. http://www.who.int/tb/publications/global_report/2008/en/index.html.
3. Barker L.F., Brennan M.J., Rosenstein P.K., Sadoff J.C. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009, 21(3):331-338.
4. Aagaard C., Dietrich J., Doherty M., Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 2009, 87(4):279-286.
5. Kaufmann S.H.E., Parida S.K. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 2010, 22:374-384.
6. Kaufmann S.H.E. Tuberculosis vaccines - a new kid on the block. Nat Med 2011, 17(2):159-160.
7. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17(2):189-194.
8. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000, 68(2):791-795.
9. Stukova M.A., Sereinig S., Zabolotnyh N.V., Ferko B., Kittel C., Romanova J., et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis 2006, 86(3-4):236-246.
10. Krammer F., Schinko T., Messner P., Palmberger D., Ferko B., Grabherr R. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J Virol Methods 2010, 167(1):17-22.
11. Xu J., Xu W., Chen X., Zhao D., Wang Y. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine 2008, 26(35):4519-4525.
12. Brodin P., Rosenkrands I., Andersen P., Cole S.T., Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 2004, 12(11):500-508.
13. Mustafa A.S., Oftung F., Amoudy H.A., Madi N.M., Abal A.T., Shaban F., et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 2000, 30(Suppl. 3):S201-S205.
14. Renshaw P.S., Panagiotidou P., Whelan A., Gordon S.V., Hewinson R.G., Williamson R.A., et al. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10 and the ESAT-6.CFP-10 complex: implications for pathogenesis and virulence. J Biol Chem 2002, 277:21598-21603.
15. Skrastina D., Bulavaite A., Sominskaya I., Kovalevska L., Ose V., Priede D., et al. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers. Vaccine 2008, 26(16):1972-1981.
16. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44(2-3):98-114.
17. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(4):499-508.
18. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337(1):149-161.
19. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A " universal" human influenza A vaccine. Virus Res 2004, 103(1-2):173-176.
20. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1157-1163.
21. Gregson A.L., Oliveira G., Othoro C., Calvo-Calle J.M., Thorton G.B., Nardin E., et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS ONE 2008, 3(2):e1556.
22. Oliveira G.A., Wetzel K., Calvo-Calle J.M., Nussenzweig R., Schmidt A., Birkett A., et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005, 73(6):3587-3597.
23. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Wetzel K., Maier C., Birkett A.J., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004, 72(11):6519-6527.
24. Skamel C., Ploss M., Bottcher B., Stehle T., Wallich R., Simon M.M., et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J Biol Chem 2006, 281(25):17474-17481.
25. Whitacre D.C., Lee B.O., Milich D.R. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 2009, 8(11):1565-1573.
26. Broos K., Janssens M.E., De Goeyse I., Vanlandschoot P., Leroux-Roels G., Geysen D., et al. Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit. Clin Vaccine Immunol 2008, 15(5):852-858.
27. Yin Y., Zhang J., Dong D., Liu S., Guo Q., Song X., et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis. Vaccine 2008, 26(46):5814-5821.
28. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 2002, 168(10):4951-4959.
29. Carpenter Z.K., Williamson E.D., Eyles J.E. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release 2005, 104(1):67-77.
30. Clarke B.E., Newton S.E., Carroll A.R., Francis M.J., Appleyard G., Syred A.D., et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987, 330(6146):381-384.
31. Francis M.J., Hastings G.Z., Brown A.L., Grace K.G., Rowlands D.J., Brown F., et al. Immunological properties of hepatitis B core antigen fusion proteins. Proc Natl Acad Sci U S A 1990, 87(7):2545-2549.
32. Ulrich R., Nassal M., Meisel H., Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998, 50:141-182.
33. Abebe F., Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol 2009, 157(2):235-243.
34. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999, 3(6):771-780.
35. Lee B.O., Tucker A., Frelin L., Sallberg M., Jones J., Peters C., et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 2009, 182(11):6670-6681.
36. Kratz P.A., Bottcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci U S A 1999, 96(5):1915-1920.
37. Nassal M., Skamel C., Vogel M., Kratz P.A., Stehle T., Wallich R., et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int J Med Microbiol 2008, 298(1-2):135-142.
38. Smith J., Manoranjan J., Pan M., Bohsali A., Xu J., Liu J., et al. Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect Immun 2008, 76(12):5478-5487.
39. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18(4):329-337.
40. Billaud J.N., Peterson D., Barr M., Chen A., Sallberg M., Garduno F., et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 2005, 79(21):13656-13666.
41. Billaud J.N., Peterson D., Schodel F., Chen A., Sallberg M., Garduno F., et al. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J Virol 2005, 79(21):13641-13655.
42. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londono-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26(51):6503-6507.